2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide profile

2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide is a complex organic molecule with a rather long and unwieldy name. It's often shortened to **compound X** or a similar designation in research papers.

**Here's a breakdown of its structure and potential importance:**

* **Structure:**
* **Imidazole ring:** The core of the molecule is an imidazole ring, a five-membered ring containing two nitrogen atoms. The imidazole ring is substituted with a nitro group (NO2) at the 2-position.
* **Acetamide group:** The imidazole ring is connected to an acetamide group, which consists of an acetyl group (CH3CO-) linked to a nitrogen atom.
* **Pentafluoropropyl group:** The nitrogen atom of the acetamide is further attached to a pentafluoropropyl group (CF3CF2CH2-).

**Potential Research Importance:**

This compound is likely being investigated for its potential biological activity. Here's why:

* **Imidazole ring:** Imidazole rings are commonly found in pharmaceuticals and bioactive compounds. They often interact with biological targets like enzymes or receptors.
* **Nitro group:** The nitro group is known to enhance the electron-withdrawing properties of the molecule. This can influence its reactivity and interactions with biological targets.
* **Pentafluoropropyl group:** Fluorinated compounds are often used in drug design to improve pharmacokinetic properties (how the drug is absorbed, distributed, metabolized, and excreted).

**Possible Areas of Research:**

* **Antimicrobial activity:** Imidazoles and their derivatives are known to have antimicrobial properties. The specific modifications in this compound might be explored to improve its effectiveness against certain bacteria or fungi.
* **Antiparasitic activity:** Imidazoles are also investigated for their potential against parasitic infections.
* **Cancer research:** Imidazoles are sometimes explored as potential anticancer agents.
* **Other biological activities:** The unique structure of this compound could lead to interesting interactions with other biological systems.

**Important Note:** Without specific research publications mentioning this compound, it's impossible to say definitively why it's important or what specific research activities are ongoing.

If you have more context, like a specific research paper or a scientific project, I can provide more tailored information.

2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide: a pentafluorinated derivative of etanidazole [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	389053
CHEMBL ID	2392845
SCHEMBL ID	365988
MeSH ID	M0252732

Synonym
nsc684681
[18F]EF5 ,
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-[18f]pentafluoropropyl)-acetamide
nsc-684681
ef-5
1h-imidazole-1-acetamide,2,3,3,3- pentafluoropropyl)-
2-(2-nitroimidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide
CHEMBL2392845
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoro-propyl)acetamide
ef5 ,
152721-37-4
383hj2t87o ,
unii-383hj2t87o
2-nitro-1-h-imidazole-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide
SCHEMBL365988
ef5, >=98% (hplc)
DTXSID10165114
2-nitro-n-(2,2,3,3,3-pentafluoropropyl)-1h-imidazole-1-acetamide
CS-7155
HY-U00118
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)-acetamide
Q5322954
ef5;ef 5
BCP30867
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide
MS-24352
CGA72137
jggdsdpoprwscx-uhfffaoysa-n
AKOS040741688

Excerpt	Reference	Relevance
" The plasma half-life was 11."	( Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Covey, JM; Evans, SM; Hahn, SM; Koch, CJ; McKenna, WG; Rockwell, K, 2001)	0.31
" EF5's consistent half-life and clearance properties will allow quantitative analysis of EF5 binding relative to tissue oxygen levels."	( Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Covey, JM; Evans, SM; Hahn, SM; Koch, CJ; McKenna, WG; Rockwell, K, 2001)	0.31
" In pharmacokinetic evaluations, in the presence of non-radioactive EF5, a uniform and low background uptake and high in vivo stability of [(18)F]EF5 have been demonstrated."	( Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5. Bergman, J; Eskola, O; Forsback, S; Grönroos, TJ; Haaparanta, M; Härkönen, P; Komar, G; Minn, H; Solin, O; Tuomela, J, 2012)	0.38

Assay ID	Title	Year	Journal	Article
AID753675	Octanol-water partition coefficient, log P of the compound	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Synthesis of new 18F-radiolabeled silicon-based nitroimidazole compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	17 (19.32)	18.2507
2000's	49 (55.68)	29.6817
2010's	20 (22.73)	24.3611
2020's	2 (2.27)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (6.67%)	5.53%
Reviews	4 (4.44%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	80 (88.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.08	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	2	1	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
celecoxib [no description available]	2	1	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
etanidazole Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.	13.22	87	5	C-nitro compound; imidazoles; monocarboxylic acid amide	alkylating agent; antineoplastic agent; prodrug; radiosensitizing agent
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	2.4	2	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.15	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
phenylhydrazine [no description available]	1.99	1	0	phenylhydrazines	xenobiotic
thiazoles [no description available]	2	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	6.37	11	0	C-nitro compound; imidazoles	antitubercular agent
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	3.11	1	0	manganese group element atom
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	2.04	1	0
fluorides [no description available]	2.08	1	0	halide anion; monoatomic fluorine
fialuridine [no description available]	2.04	1	0
pimonidazole pimonidazole: structure given in first source	4.35	7	0
carbogen carbogen: mixture of 95% O2 & 5% CO2	2.7	3	0
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.93	3	0	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	2.1	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
fluoromisonidazole [no description available]	2.04	1	0
calcium borate calcium borate: RN given refers to cpd with MF CaB4O7	2	1	0
atrasentan Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.	2.05	1	0	pyrrolidines
technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.	2	1	0
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2	1	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.1	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
3,3'-diheptyloxycarbocyanine [no description available]	2	1	0
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.7	3	0	cyanine dye; organic iodide salt	fluorochrome
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.05	1	0	gadolinium coordination entity	MRI contrast agent
pr-104a PR-104A: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; PR-104A is the corresponding alcohol of PR104	2.15	1	0
pr-104 PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source	2.25	1	0
arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.	2.04	1	0
5-(2,2-dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-pyrroline n-oxide 5-(2,2-dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-pyrroline N-oxide: structure in first source	2.07	1	0
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	2.71	3	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2	1	0
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol: a radiosensitizing agent used for PET imaging of hypoxia; structure in first source	3.17	1	0
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.72	3	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
cyanine dye 3 cyanine dye 3: structures of Cy3 derivatives given in first source	2.41	2	0

Condition	Relationship Strength	Studies	Trials
Anoxemia [description not available]	8.78	26	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	8.78	26	1
Benign Neoplasms [description not available]	8.07	14	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	8.07	14	1
Arthritis, Degenerative [description not available]	2.25	1	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.25	1	0
Cancer of Head [description not available]	6.16	6	2
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	6.16	6	2
Local Neoplasm Recurrence [description not available]	4.13	3	0
Carcinoma, Non-Small Cell Lung [description not available]	2.08	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.49	2	0
Cancer of Lung [description not available]	2.45	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.08	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.45	2	0
Malignant Melanoma [description not available]	2.1	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.1	1	0
Adenocarcinoma, Basal Cell [description not available]	3.67	3	0
Carcinoma, Anaplastic [description not available]	2.71	3	0
Experimental Neoplasms [description not available]	3.27	6	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.67	3	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.71	3	0
Colorectal Cancer [description not available]	3.38	2	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.38	2	0
Carcinoma, Oat Cell [description not available]	2.96	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.62	3	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.96	1	0
Benign Neoplasms, Brain [description not available]	5.9	5	1
Astrocytoma, Grade IV [description not available]	4.75	2	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	5.9	5	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	4.75	2	1
Cancer of Colon [description not available]	3.1	5	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.1	5	0
Adjuvant Arthritis [description not available]	2.05	1	0
Bone Loss, Osteoclastic [description not available]	2.05	1	0
Glial Cell Tumors [description not available]	4.43	8	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	4.43	8	0
Atherogenesis [description not available]	2.06	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.27	6	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.06	1	0
Animal Mammary Carcinoma [description not available]	1.99	1	0
Anoxia, Brain [description not available]	2.7	3	0
Anterior Circulation Transient Ischemic Attack [description not available]	2.41	2	0
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.41	2	0
Hepatocellular Carcinoma [description not available]	2.01	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.01	1	0
Cancer of Muscle [description not available]	2.01	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	3.11	5	0
Hyperoxia An abnormal increase in the amount of oxygen in the tissues and organs.	2.02	1	0
Cancer of Cervix [description not available]	4.31	4	1
Lymph Node Metastasis [description not available]	2.02	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	4.31	4	1
Gastrointestinal Stromal Neoplasm [description not available]	2.02	1	0
Cancer of Gastrointestinal Tract [description not available]	4.72	2	1
Cancer of Ovary [description not available]	2.02	1	0
Sarcoma, Epithelioid [description not available]	5.7	4	1
Appendiceal Cancer [description not available]	2.02	1	0
Appendiceal Neoplasms Tumors or cancer of the APPENDIX.	2.02	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.02	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	5.7	4	1
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	2.02	1	0
Breast Cancer [description not available]	2.02	1	0
Angiogenesis, Pathologic [description not available]	3.1	5	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.02	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.92	4	0
Experimental Mammary Neoplasms [description not available]	2.93	4	0
Carcinoma, Epidermoid [description not available]	4.32	4	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	4.32	4	1
Cancer of Larynx [description not available]	2.03	1	0
Cancer of Mouth [description not available]	2.03	1	0
Cancer of Oropharnyx [description not available]	2.03	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.03	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.03	1	0
Oropharyngeal Neoplasms Tumors or cancer of the OROPHARYNX.	2.03	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.04	1	0
Cerebral Ischemia [description not available]	2.7	3	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.7	3	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.04	1	0
Cancer of Prostate [description not available]	2.04	1	0
Hormone-Dependent Neoplasms [description not available]	2.04	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.04	1	0
EHS Tumor [description not available]	2.4	2	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1.99	1	0
Experimental Hepatoma [description not available]	2.4	2	0
Cardiovascular Stroke [description not available]	1.99	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	1.99	1	0
Chronic Illness [description not available]	2	1	0
Abnormality, Heart [description not available]	2	1	0
Acute Disease Disease having a short and relatively severe course.	2	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2	1	0
Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.	2	1	0
Anterior Choroidal Artery Infarction [description not available]	2	1	0
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	2	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	4.31	1	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.01	1	0
Cancer, Radiation-Induced [description not available]	2.01	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.01	1	0

2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide

Description

Cross-References

Synonyms (29)

Research Excerpts

Pharmacokinetics

Bioassays (1)

Research

Studies (88)

Market Indicators

Research Demand Index: 10.00

Study Types